Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.32 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275128 | 0.98 | LMNA (0.38) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL27273733 | 0.93 | LMNA (0.41) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL28151786 | 0.93 | DNM1 (0.35) | DNM1FDPSTSHR | |
| SCHEMBL27275500 | 0.86 | OPRM1 (0.37) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL28294988 | 0.84 | LMNA (0.38) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL28003999 | 0.84 | LMNA (0.38) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL27584591 | 0.83 | TSHR (0.46) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL27922137 | 0.80 | LMNA (0.50) | LMNASMPD1FDPSTSHRGPR84 | |
| SCHEMBL27290323 | 0.79 | OPRM1 (0.37) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL10775702 | 0.77 | OPRM1 (0.42) | OPRM1LMNADNM1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481645-B2 | Composition, synthesis, and use of a new class of isonitriles | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150239835-A1 | COMPOSITION, SYNTHESIS, AND USE OF A NEW CLASS OF ISONITRILES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2015127226-A1 | COMPOSITION, SYNTHESIS, AND USE OF A NEW CLASS OF ISONITRILES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239835-A1 | COMPOSITION, SYNTHESIS, AND USE OF A NEW CLASS OF ISONITRILES | CYP3A4, UGT1A4, INTS9 | OPRM1 1328/4885LMNA 3221/4885DNM1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.